29 completed, 5 terminated, 3 unknown, 1 active not recruiting. 39 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 39 | Completed 29, Terminated 5, Unknown 3, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 2, Terminated 2, Active not recruiting 1, Unknown 1, Withdrawn 1 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduced-dose Botox for Urgency Incontinence Among Elder Females Botox 50 Unit Injection, Botox 100 Unit Injection - Overactive Bladder, Urinary Incontinence in Old Age | Phase 1 / Phase 2 | Active not recruiting | Dartmouth-Hitchcock Medical Center | 376 | 2023-05-12 | 2026-02-03 |
| Beta 3 Agonists in Treatment of Non-neurogenic Voiding Dysfunction in Children Beta3-Agonists, Adrenergic, Anticholinergic drug, Solifenacin - Voiding Disorders, Overactive Bladder | Phase 1 / Phase 2 | Unknown | Mansoura University | 70 | 2022-02-01 | 2022-02-15 |
| Acupuncture Combined With Mirabegron in the Treatment of OAB 50 mg of mirabegron, acupuncture combined with mirabegron. - Overactive Bladder | Phase 1 | Unknown | The Affiliated Ganzhou Hospital of Nanchang University | 75 | 2021-12-01 | 2023-12-26 |
| Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function BAY1817080 - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 32 | 2020-08-12 | 2024-03-26 |
| A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B) BAY1817080, [14C]BAY1817080 - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 14 | 2020-08-05 | 2023-01-26 |
| Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function BAY1817080, Midazolam - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 37 | 2020-07-23 | 2023-01-20 |
| A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers. BR9006-1, BR9006-2 - Benign Prostatic Hyperplasia (BPH), Overactive Bladder | Phase 1 | Completed | Boryung Pharmaceutical Co., Ltd | 36 | 2020-07-20 | 2020-10-28 |
| Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants BAY1817080, Moxifloxacin, Placebo - Cough, Endometriosis | Phase 1 | Completed | Bayer | 42 | 2020-06-18 | 2022-01-24 |
| Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder Botulinum toxin type A injection, Botulinum Toxin Type A Injection [Botox] - Overactive Bladder | Phase 1 | Completed | Hugel | 38 | 2020-05-12 | 2022-04-15 |
| Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants BAY1817080, Matching Placebo - Endometriosis Related Pain, Overactive Bladder | Phase 1 | Completed | Bayer | 36 | 2020-02-15 | 2023-01-26 |
| Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder Meditoxin, Botox - Overactive Bladder | Phase 1 | Completed | Medy-Tox | 30 | 2017-12-13 | 2019-03-27 |
| Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence AHLeveeS System - Overactive Bladder | Phase 1 | Completed | Neuspera Medical, Inc. | 6 | 2017-08-17 | 2018-08-22 |
| Mirabegron For Erectile Dysfunction Mirabegron - Erectile Dysfunction, Overactive Bladder | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 20 | 2017-08-01 | 2021-01-05 |
| Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel - Overactive Bladder | Phase 1 / Phase 2 | Withdrawn | UroGen Pharma Ltd. | 2016-10-01 | 2017-06-16 | |
| A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects DA-8010, Placebo - Overactive Bladder | Phase 1 | Unknown | Dong-A ST Co., Ltd. | 110 | 2016-06-01 | 2016-07-01 |
| Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB Dried Cranberry, Placebo Oral Capsule - Overactive Bladder | Phase 1 | Completed | Weill Medical College of Cornell University | 77 | 2016-04-01 | 2018-09-17 |
| Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers HIP1503, HGP1103 - Overactive Bladder | Phase 1 | Completed | Hanmi Pharmaceutical Company Limited | 36 | 2016-03-01 | 2016-10-20 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) mirabegron - Overactive Bladder, Neurogenic Detrusor Overactivity | Phase 1 | Completed | Astellas Pharma Europe B.V. | 9 | 2015-12-17 | 2024-10-31 |
| The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers. JLP-1207, Solifenacin 5mg+Tamsulosin 0.2mg - LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 54 | 2015-08-01 | 2016-06-24 |
| Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers JLP-1207(Fasted), JLP-1207(Fed) - LUTS, Benign Prostatic Hyperplasia | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 54 | 2015-07-01 | 2016-06-24 |
Showing 20 of 39. Sign in to see all of them.
Urinary Bladder, Overactive (39) · Prostatic Hyperplasia (4) · Urinary Incontinence (2) · Cough (1) · Endometriosis (1) · Erectile Dysfunction (1) · Kidney Failure, Chronic (1) · Lower Urinary Tract Symptoms (1) · Nocturia (1) · Urinary Incontinence, Urge (1)
Female Urogenital Diseases (39) · Female Urogenital Diseases and Pregnancy Complications (39) · Male Urogenital Diseases (39) · Pathological Conditions, Signs and Symptoms (39) · Signs and Symptoms (39) · Urinary Bladder Diseases (39) · Urogenital Diseases (39) · Urologic Diseases (39) · Urological Manifestations (39) · Lower Urinary Tract Symptoms (38) · Genital Diseases (6) · Genital Diseases, Male (5) · Prostatic Diseases (4) · Urination Disorders (3) · Chronic Disease (1)
mirabegron (6) · Solifenacin Succinate (5) · Tolterodine Tartrate (4) · Botulinum Toxins, Type A (3) · N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (3) · Tamsulosin (3) · solabegron (2) · Adrenergic beta-3 Receptor Agonists (1) · Cephalexin (1) · Chemoprevention (1) · Cholinergic Antagonists (1) · DA-8010 (1) · Dimethyl Sulfoxide (1) · Levofloxacin (1) · Midazolam (1)
Bayer (5) · Merck Sharp & Dohme LLC (4) · Astellas Pharma Inc (3) · GlaxoSmithKline (3) · Jeil Pharmaceutical Co., Ltd. (3) · UroGen Pharma Ltd. (2) · Urovant Sciences GmbH (2) · Amphora Medical, Inc. (1) · Astellas Pharma Europe B.V. (1) · Astellas Pharma Europe Ltd. (1) · Boryung Pharmaceutical Co., Ltd (1) · Dartmouth-Hitchcock Medical Center (1) · Dong-A ST Co., Ltd. (1) · Hanmi Pharmaceutical Company Limited (1) · Hugel (1)
United States (11) · Netherlands (4) · South Korea (4) · Belgium (3) · Denmark (3) · Poland (3) · Canada (2) · Israel (2) · Australia (1) · China (1) · France (1) · Germany (1) · Japan (1) · Norway (1) · Serbia (1)
Kyung-sang Yu, M.D., Ph.D. (2) · Ami Sidi, Prof MD (1) · An-Hye Kim (1) · Anne C Cooper, MD, MA (1) · Arthur L Burnett, M.D., M.B.A. (1) · Bilal Chughtai, MD (1) · E A Gormley, MD (1) · Gommert A. van Koeveringe (1) · Ifat Klein, PhD (1) · Islam Mansour, Mb ChB (1)
PMID 19648387, PMID 21905086, PMID 37160401, PMID 38044419, PMID 38907175
2014 (1), 2015 (1)